Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson’s Disease

Existing therapies for Parkinson’s disease (PD) are only symptomatic. As erythropoietin (EPO) is emerging for its benefits in neurodegenerative diseases, here, we test the protective effect driven by EPO in in vitro (SH-SY5Y cells challenged by MPP(+)) and in vivo (C57BL/6J mice administered with MP...

Descripción completa

Detalles Bibliográficos
Autores principales: Rey, Federica, Ottolenghi, Sara, Giallongo, Toniella, Balsari, Alice, Martinelli, Carla, Rey, Robert, Allevi, Raffaele, Giulio, Anna Maria Di, Zuccotti, Gian Vincenzo, Mazzucchelli, Serena, Foresti, Roberta, Samaja, Michele, Carelli, Stephana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830512/
https://www.ncbi.nlm.nih.gov/pubmed/33467745
http://dx.doi.org/10.3390/antiox10010121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830512/
https://www.ncbi.nlm.nih.gov/pubmed/33467745
http://dx.doi.org/10.3390/antiox10010121

Ejemplares similares